Relay Therapeutics, Inc. (RLAY)

Over the past six months, Relay Therapeutics' stock (RLAY) has experienced significant activity, with a return of +152.7%. Oppenheimer and Wells Fargo & Company upgraded Relay Therapeutics' stock. The FDA granted Breakthrough Therapy designation to zovegalisib (RLY-2608) plus fulvestrant for PIK3CA-mutant, HR+/HER2- advanced breast cancer, leading to a 6.4% increase in the stock price. The company reported ($0.43) EPS for the quarter ending November 6, 2025, missing analysts' consensus estimates of ($0.39). Several insiders sold shares in late January 2026 to cover income tax withholding obligations. Positive clinical data from the ReDiscover program in breast cancer on December 12, 2025, resulted in a positive stock movement.

As a clinical-stage biotechnology company, Relay Therapeutics, Inc. does not have commercialized products or services that would exhibit traditional demand seasonality. Demand seasonality for its products and services is not applicable at this stage. However, historical stock price data suggests some seasonality in stock returns, with June showing the highest probability of positive returns at 100%, while February has a 40% probability.

Relay Therapeutics, Inc. is a clinical-stage precision medicines company focused on transforming drug discovery within the Healthcare sector and Biotechnology industry. The company utilizes its Dynamo platform to enhance small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its pipeline includes clinical-stage product candidates such as RLY-1971, RLY-4008, RLY-PI3K1047, RLY-2608 (zovegalisib), aGal chaperone, RLY-8161, and RLY-1013.

Relay Therapeutics, Inc. is headquartered in Cambridge, Massachusetts, USA, with its primary operational and market focus within the United States.

Relay Therapeutics' brand reputation over the past year appears to be generally positive, driven by clinical progress and analyst sentiment. The company has received a consensus rating of "Moderate Buy" from MarketBeat, with an average price target of $16.57, and a "Strong Buy" consensus from 8 analysts with an average price target of $15.75. The FDA's Breakthrough Therapy designation for zovegalisib in early February 2026 is a significant positive event. While Weiss Ratings reissued a "sell (d-)" rating in January 2026, the overall analyst sentiment has trended more positive with upgrades from Oppenheimer and Wells Fargo.

Relay Therapeutics, Inc. has a substantial institutional ownership base, with 357 institutional owners and shareholders holding a total of 179,917,186 shares. Major institutional owners include SB Investment Advisers (UK) Ltd, Commodore Capital Lp, Point72 Asset Management, L.P., BlackRock, Inc., Casdin Capital, LLC, Vanguard Group Inc, Bellevue Group AG, Tang Capital Management Llc and State Street Corp. Approximately 9.93% to 22.50% of the company's stock is owned by Institutional Investors, 2.55% by Insiders, and the remaining by Public Companies and Individual Investors.